(Q35949091)

11 August 2017

1 reference

title

Cure of myeloma: hype or reality? (English)

1 reference

11 August 2017

Fassas A

1

1 reference

11 August 2017

Shaughnessy J

series ordinal

2

1 reference

11 August 2017

Barlogie B

series ordinal

3

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Bone Marrow Transplantation

11 August 2017

published in

1 reference

11 August 2017

volume

35

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

215-224

1 reference

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

VAD-based regimens as primary treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Moving disease biology from the laboratory to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Thalidomide in the management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

Hypodiploidy is a major prognostic factor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704757

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704757

1 reference

11 August 2017

1 reference